| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T56 |
0-85 |
Sentence |
denotes |
We can assume that virus-based vaccines should prove valuable in combatting COVID-19. |
| T57 |
86-306 |
Sentence |
denotes |
In addition to the entire virus particle-associated inactivated or attenuated viral vaccines, the subunit candidates, such as S1 protein and/or the RBD element of SARS-CoV-2, are also valuable targets for vaccine design. |
| T58 |
307-599 |
Sentence |
denotes |
Combining subunit vaccines with established or new adjuvants such as alum versus modern adjuvants such as the GSK AS series of adjuvants may represent a faster and safer strategy to move through early clinical development with the caveat that the protective efficacy may not be strong enough. |
| T59 |
600-757 |
Sentence |
denotes |
As a result, immunizing the subunit vaccines with proper delivery platforms and immunization strategies to enhance the immune responses should be considered. |
| T60 |
758-918 |
Sentence |
denotes |
We expect researchers who are racing against time will bring a new SARS-CoV-2-based vaccine from gene sequence to clinical testing in approximately 16–20 weeks. |
